High Throughput Screening Market Worth USD 21,911.2 Million By 2022
The Global High Throughput Screening Market will grow at a
CAGR of 8.0% from 2017 to 2022 to reach USD 21,911.2 million by 2022, according
to the latest publication from Meticulous Research®. The global high
throughput screening market is primarily driven by the increasing adoption of
innovative approaches in pharmaceutical and biotechnology companies, rising
investment by private equity firms and venture capitalists, increasing government
funding for various R&D activities, growing healthcare spending, and
various technological advancements in this field. Further, growing research in
toxicology and stem cell research provide significant opportunities in this
market. However, high cost for HTS, intricacy in the field of assay
development, and government regulations for drug development obstructs the
growth of this market to some extent.
The global high
throughput screening market is mainly segmented by product & service
(Consumables & Reagents, Instruments, Software & Services), by
technology (Cell-based Assay, Ultra High Throughput Screening, Label-Free
Technology, Lab On A Chip), by application (Stem Cell Research, Toxicology
Assessment, Primary Screening, Target Identification), by end user
(Pharmaceuticals and Biotechnology Industry, Academics and Research Institutes,
Contract Research Organizations, and others), and by geography (North America,
Europe, Asia-Pacific, Latin America, and Middle East & Africa).
Browse in-depth Report at //www.meticulousresearch.com/product/high-throughput-screening-market-forecast/
Based on products, the
consumables & reagents segment dominated the overall market in 2016 and is
also estimated to continue its dominance over the forecast period, owing to the
availability of a wide variety of reagents, rising demand for consumables &
reagents with increasing adoption of HTS in drug discovery, and continuous launch
of innovative technology-based products in the global market.
Based on technology,
cell-based assay segment commanded the largest share in 2016, owing to the
large adoption of cell-based platforms to gain accurate and more relevant in
vivo biological information in high-throughput drug screenings for
target validation and ADMET (absorption, distribution, metabolism, elimination,
and toxicity) in drug discovery.
On the basis of
application, target identification segment held the largest share of the global
high throughput screening market in 2016, owing to the rising adoption of
high-throughput products for efficient, faster, and cost-effective
identification of targets in early-stage drug discovery.
Request-Sample-Report
:https://www.meticulousresearch.com/request-sample-report/?cp_id=3206
Based on the end user,
the pharmaceuticals & biotechnology industry dominated the high throughput
screening market in 2016, owing to higher adoption of high throughput screening
assay for drug discovery and development and regenerative medicine in this
industry.
Geographically, North
America accounted for the major share of the global high throughput screening
market in 2016, followed by Europe and Asia-Pacific region. The major share of
the North American region is mainly attributed to the higher spending on
pharmaceutical R&D, higher adoption of advanced HTS technologies in drug
discovery & development, well-established healthcare system, availability
of government funding, and the presence of leading players in this region.
However, Asia-Pacific region is slated to register the fastest growth during
the forecast period, primarily due to rising R&D expenditure, increasing
pharmaceutical research outsourcing in the region owing to lower cost
advantages, increasing government funding, and improving healthcare
infrastructure. In addition, significantly growing pharmaceutical industry in
Asia, primarily due to huge demand for medical care from large population base
with increasing incidence & prevalence of chronic disease and aging
population are expected to support the growth of HTS market in the region.
The leading companies
have employed various strategies to expand their product and application
offerings, global footprint, and augment their market shares. The key strategies
followed by most companies in the global high throughput screening market were
new product launches, mergers & acquisitions, and expansions. The key
players in the global high throughput screening market are MERCK KGaA, Charles
River Laboratories International, Inc., AXXAM S.p.A., Thermo Fisher Scientific
Inc., Danaher Corporation, PerkinElmer Inc., Agilent Technologies Inc., Bio-Rad
Laboratories, Inc., Tecan Trading AG, Aurora Biomed, Inc., and Hamilton
Company.
About Meticulous Research®
MeticulousResearch® is founded in 2010 and incorporated
as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company
under the Companies Act, 1956. Since its incorporation, the company has become
the leading provider of premium market intelligence in North America, Europe,
Asia-Pacific, Latin America, and Middle East & Africa.
Contact
Us:
Viren Shrivastava
Viren Shrivastava
AVP-
Global Sales and Marketing
Meticulous
Research®
Tel:
+1-646-781-8004
Email: viren@meticulousresearch.com
Comments
Post a Comment